|April 08, 2003
|Webcast Alert: Hemispherx BioPharma, Inc. Announces HEB Presentation at Redchip Partners New York Investor Conference 2003 Webcast
|Philadelphia, PA, Tuesday, April 08, 2003: PHILADELPHIA, April 8, 2003 -- Hemispherx BioPharma, Inc. (Amex: HEB ) announces the following Webcast:
What: HEB Presentation at Redchip Partners New York Investor
When: April 8, 2003 @ 8:30 am EDT
How: Live over the Internet -- Simply log on to the web at the
Contact: Nicholas Furnari, +1-212-495-0200, email@example.com,
for Hemispherx BioPharma, Inc.
If you are unable to participate during the live webcast, the call will be archived at www.Hemispherx.net.
Hemispherx BioPharma, based in Philadelphia, is a biopharmaceutical company engaged in the global clinical development, manufacture, marketing and distribution of drug entities based on immune system enhancing technologies.
Its lead compounds are Alferon®, a natural form of Interferon currently approved by the FDA for a category of sexually transmitted genital diseases, and Ampligen® a nucleic acid which is in Phase IIb clinical trials for HIV/AIDS and Phase III clinical trials for Chronic Fatigue Syndrome.
The Company's platform technologies include a large and small agent components for potential treatment of various chronic viral infections, including HIV, Chronic Fatigue Syndrome and Hepatitis.
For more information visit the company's Web site at www.Hemispherx.net.
(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp and at least a 28.8 kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to firstname.lastname@example.org .)
Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223
Robert Giordano, MRB Investor Relations
(212) 495-0200, Fax: (212) 495-0746
HEB's Web Site: www.hemispherx.net